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Abstract
Ginseng polysaccharide has been known to have multiple immunomodulatory effects. In this study, we investigated
whether Panax ginseng polysaccharide (GP) would have a preventive effect on influenza infection. Administration of mice
with GP prior to infection was found to confer a survival benefit against infection with H1N1 (A/PR/8/34) and H3N2 (A/
Philippines/82) influenza viruses. Mice infected with the 2009 H1N1 virus suspended in GP solution showed moderately
enhanced survival rates and lower levels of lung viral titers and the inflammatory cytokine (IL-6). Daily treatment of
vaccinated mice with GP improved their survival against heterosubtypic lethal challenge. This study demonstrates the first
evidence that GP can be used as a remedy against influenza viral infection.
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Introduction
Influenza is a serious respiratory disease causing recurrent
outbreaks significantly affecting human health, livestock, and the
global economy. Diverse influenza A viruses with different
combinations of hemagglutinin (H1 to H16) and neuraminidase
(N1 to N9) subtypes have been identified [1]. The new 2009 H1N1
influenza virus spread rapidly to over 74 countries around the
world by early June 2009, when the World Health Organization
raised the global outbreak alert level to the pandemic phase. [2–5].
Current vaccines are only effective if they are well matched with
the predicted influenza strains that circulate during the next
season. In addition, a number of influenza variants have evolved to
develop resistance to antiviral drugs [6]. A preventive measure that
would have protective effects on influenza virus regardless of strain
is highly desirable.
An acidic polysaccharide from Panax ginseng (ginseng polysac-
charide) has been shown to display immunomodulatory effects
either in an immuno-stimulatory or in an immuno-suppressive
manner depending on timing of treatments and disease environ-
ments. Ginseng polysaccharide (GP) promoted the production of
cytotoxic cells against tumors and stimulated macrophages to
produce helper types 1 and 2 (Th1 and Th2) cytokines [7–14]. GP
was also shown to modulate the antioxidant defense systems such
as superoxide dismutase and glutathione peroxidase enzymes
probably via inducing regulatory cytokines [9,15]. As an anti-
inflammatory function, recent studies reported that pretreatment
with GP suppressed acute inflammatory responses at an early
phase resulting in the enhancement of antimicrobial activities and
protection of mice from Staphylococcus aureus-induced sepsis [16,17].
However, the effects of GP on viral infection remain unknown.
In this study, we have investigated the potential effects of GP on
survival outcomes after influenza viral infection in a mouse model.
Also, the potential roles of GP in conferring protection to naı ¨ve
mice and in improving cross-protection of vaccinated mice have
been explored and discussed.
Materials and Methods
Cells, virus, and reagents
Spodoptera frugiperda sf9 insect cells purchased from the American
Type Culture Collection (ATCC, CRL-1711) were used for the
production of recombinant baculoviruses (rBVs) and virus-like
particles (VLPs) as an influenza vaccine candidate, and were
cultured in SF900-II serum-free medium (GIBCO-BRL) at 27uC
in spinner flasks. The influenza subtype H1N1 A/PR/8/34 (A/
PR8) and H3N2 A/Philippines/82 viruses were kindly provided
by Dr. Huan Nguyen, and the new 2009 H1N1 influenza virus
(A/California/04/2009) by Dr. Richard Webby. Influenza viruses
were grown in 11-day old embryonated hen’s eggs. Egg allantoic
fluids were harvested and stored at 280uC until use. Madin-Darby
canine kidney (MDCK) cells purchased from ATCC were
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used to determine virus titers from egg allantoic fluids and mouse
lung homogenates by a plaque assay [18]. Mice were infected with
serial dilutions of influenza virus and the 50% lethal dose (LD50)
was determined. The ginseng polysaccharide (GP) reagent used in
this study was obtained from the Korea Ginseng Corporation.
Briefly, red ginseng (P. ginseng) was percolated with 5 volumes of
85% ethanol to extract off ethanol-soluble materials. The
remaining residues were re-percolated with 5 volumes of distilled
water, and the water-soluble extracts were concentrated with a
vacuum evaporator. The concentrate was dialyzed against water
to completely cut off small molecules of less than 15 kDa. Four
volumes of absolute ethanol were added to precipitate the
polysaccharide in the inner dialysate. The precipitate was dried
in a vacuum drying oven, and was finally used as a red ginseng
acidic polysaccharide (GP) as previously described [11,19,20]. An
active acidic polysaccharide moiety (Table 1, Fig. 1) present in GP
was reported to be composed of a galactogalacturonan core such
as a-D-Galacturonic acid-(1-4)-a-D-Galacturonic acid-(1-4)-a-D-
Galacturonic acid-(1-6)-a-D-Galactose [20]. GP is also known to
contain sugars composed of a(1-6) glucopyranoside and b(2-6)
fructofuranoside [11,16]. As a quality control, the endotoxin
content in GP preparations was less than the threshold level
(0.006 EU/mg) as determined by the Limulus amebocytes lysates
assay (EndosafeJ, Charles River Laboratories, USA) according to
the manufacturer’s instructions [16,20,21].
Ginseng polysaccharide pretreatment of mice and
influenza virus infection
A powder form of GP was dissolved in phosphate-buffered
saline (PBS, pH 7.4), filtered through 0.4 mm Millipore mem-
branes. For animal experiments, 8–10 weeks old BALB/c mice
(Harlan Laboratories, Indianapolis, IN) were lightly anesthetized
with isoflurane inhalation and then GP was administered
intranasally or intravenously in a dose ranging from 12.5 to
50 mg/kg weight. To determine the effects of GP treatment on
influenza infection, mice (n=6 to 10 per group) were anesthetized
by isoflurane inhalation and intranasally infected by mouse-
adapted pathogenic strains of A/PR8 or A/Philippines/82. Mice
were monitored daily to record weight changes and mortality. All
animal experiments and husbandry involved in the studies
presented in this manuscript were conducted under the guidelines
of the Emory University Institutional Animal Care and Use
Committee (IACUC). Emory IACUC operates under the federal
Animal Welfare Law (administered by the USDA) and regulations
of the Department of Health and Human Services. Emory
University IACUC specifically approved full details of this study as
proposed by the approved IACUC DAR-2000161-081313.
Lung viral titers and cytokine assays
Lung viral titers were performed using MDCK cells as
previously described [22]. Lungs were collected at day 4 post
infection. Briefly, serially diluted lung extracts were added to six-
well plates containing confluent MDCK cell monolayers, and
incubated at 37uC for 1 h. Overlay medium containing DEAE
dextran, nonessential amino acids, glutamine, and trypsin were
added and incubated for 2 or 3 days. After fixing with 0.25%
glutaraldehyde and staining with 1% crystal violet, the plaques
were counted. Cytokine ELISA was performed as described
previously [23]. Ready-Set-Go interferon (IFN) c and interleukin
(IL)-6)- kits (eBioscience, San Diego, CA) were used for detecting
cytokine levels in lung extracts following the manufacturer’s
recommended procedures.
Figure 1. A proposed chemical structure of active substance of red ginseng acidic polysaccharides (GP). A proposed partial structure of
polysaccharides present in GP was suggested in a previous study [20]. A proposed active component of GP comprises a galactogalacturonan core
such as a-D-Galacturonic acid-(1-4)-a-D- Galacturonic acid-(1-4)-a-D- Galacturonic acid-(1-6)-a-D-Galactose as the acidic moiety [20].
doi:10.1371/journal.pone.0033678.g001
Table 1. The composition of red ginseng acidic
polysaccharide (GP)*.
Composition Molar ratios (%)
Glucuronic acid (acidic) 51.8
Galacturonic acid (acidic) 5.1
Glucose (Neutral) 26.1
Arabinose (Neutral) 1.6
Protein ,0.1
*GP has heterogeneous molecular weights with a range of 12 KDa to 450 KDa.
[20].
doi:10.1371/journal.pone.0033678.t001
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and virus
Different concentrations of ginseng polysaccharide (25 ml) or PBS
buffer control were mixed with influenza virus (25 ml with 3 LD50)
and incubated at room temperature for 30 min. The virus and
ginseng polysaccharide mixtures were administered to naı ¨ve mice,
and body weight changes and survival rates were monitored daily.
Treatment of vaccinated mice with GP and
heterosubtypic challenge
To vaccinate mice, influenza VLPs containing hemagglutinin
(HA) and matrix (M1) proteins from H1N1 A/PR8 virus were
prepared as described previously [18]. Mice were intramuscularly
vaccinated with influenza VLPs (8 mg total protein per mouse) one
time followed by daily administration with GP (0.1 mg) intrana-
sally for 12 days from the day 1 post vaccination. On day 13 post
vaccination, vaccinated mice were challenged with a lethal dose of
H3N2 heterosubtypic virus (A/Philippines/82, 6 LD50). Body
weight changes and survival rates were monitored daily.
Antibody determination and hemagglutination activity
assay
Influenza virus-specific total IgG antibodies were determined
using standard methods as described previously [18,24]. Briefly,
inactivated influenza virus was used as an antigen on 96 well
microtiter plates (Nunc, Rochester, NY) in coating buffer (0.1 M
sodium carbonate, pH 9.5). Serially diluted serum samples were
added and incubated for 1 hr at 37uC, and then horseradish
peroxidase (HRP) -conjugated goat anti-mouse IgG antibody was
used as secondary antibody and O-phenylenediamine as a
substrate. Antibody levels are presented based on optical
spectrophotometer readings at 450 nm (OD450).
For determination of hemagglutination activity as a measure of
viral growth, virus culture supernatants were diluted, mixed with
0.5% chicken red blood cells, and then incubated for 1 hour at
room temperature. The dilutions showing a blood cell precipitated
spot were used as an endpoint as described previously [18,24].
Statistical analysis
To determine the statistical significance, a two-tailed Student’s
t-test was used when comparing two different groups. A p value
less than 0.05 was considered to be significant.
Results
Ginseng polysaccharide protects mice from lethal
infection with H1N1 influenza virus
We have investigated the effects of ginseng polysaccharide (GP)
on conferring protection against lethal infection with influenza
virus in a mouse model. Mice (BALB/c) were intranasally
administered 25 mg GP/kg body weight. At six hours after
treatment with GP, the treated or naı ¨ve mice were intranasally
infected with a lethal dose (3 LD50) of influenza H1N1 virus A/
PR/8/34 (LD50: 50% lethal dose) and monitored daily for
morbidity (body weight changes) and mortality (survival rates). As
shown in Fig. 2A, naı ¨ve (untreated) mice showed severe body
weight loss over 25% and died or were euthanized by day 8 post
infection with A/PR/8/34. GP treated mice exhibited a
significant delay in body weight loss although these mice also
showed approximately 20–25% loss in body weight (Fig. 2A).
Importantly, the GP treated mice all survived lethal infection
(Fig. 2B). When mice were treated with GP at an earlier time point
24-hr before infection, 30% of GP treated mice were protected
while none of the naı ¨ve control group survived challenge infection
with A/PR/8/34 (3 LD50).
To determine the dosage effects of GP, different doses of GP
were similarly tested in mice with the same challenge dose (3 LD50)
as summarized in the Table 2. The lowest dose of GP (12.5 mg/
kg) provided only partial protection of 60% of the treated mice
indicating less protective efficacy (Table 2). The higher dose
(50 mg GP/kg) provided 80–100% protection following severe
Figure 2. Ginseng polysaccharide pretreatment provided protection against lethal infection with H1N1 influenza virus. A) Changes in
body weight (%). B) Survival rates (%). BALB/c mice (n=10, 12 weeks old) were pretreated once intranasally with ginseng polysaccharide (25 mg/kg
weight) 6 hours prior to infection with 150 plaque-forming units (pfu) of A/PR/8/34 virus (3 LD50). Mock: mice treated with PBS, GP: mice treated
ginseng polysaccharide. * p,0.05 between mock and GP groups as determined by Student’s t-test.
doi:10.1371/journal.pone.0033678.g002
Table 2. Dosage effects of GP on protection against influenza
virus (A/PR/8/34)*.
GP dosage (mg GP/Kg) Survival (%) Weight loss (%)
00 .25
12.5 60 20–25
25 100 20–25
50 90–100 20–25
*Each group has 5–10 mice. GP was intranasally administered to mice with the
given dose.
doi:10.1371/journal.pone.0033678.t002
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higher dose of GP.
Ginseng polysaccharide confers protection against lethal
infection with H3N2 influenza virus
To test if the protective effects of GP extended to a different
subtype influenza virus, the A/Philippines/82 (H3N2 subtype) was
used as a challenge virus (Fig. 3). The GP treated or naı ¨ve mice
were challenged with a sub-lethal dose of A/Philippines/82 virus
(2 LD50). Less body weight loss (15–20%) was observed in the GP
treated compared to naı ¨ve mice that showed 25% average body
weight loss (Fig. 3A). Also, the survival rates of GP-administered
and naı ¨ve mice were 100% and 33% respectively (Fig. 3B). To
better understand the effects of GP on improving protection, we
determined viral loads at an early stage of infection and host
responses in the surviving mice. 2.5 fold lower lung viral titers were
observed in the GP-treated mice compared to the naı ¨ve control
(Fig. 3C, p,0.05).
As an alternative route of delivery, different doses (10, 25 mg/
kg) of GP were administered to mice intravenously 6 hr before
infection with A/Philippines/82 virus (3 LD50). The low dose
10 mg/kg group showed 100% survival rate whereas a partial
protection of 66% was observed in the 25 mg/kg group (Fig. 4).
Nonetheless, the surviving mice in both groups showed severe
body weight loss (Fig. 4A). All naı ¨ve mice died after infection with
the same dose of A/Philippines/82 virus (3 LD50). Thus, GP might
be partially effective in conferring protection through intravenous
administration but high doses of GP would not enhance the
survival protection. The results suggest that an optimal dose of GP
administration confers the host with improved capacity to protect
against lethal infection with H3N2 influenza strain.
Ginseng polysaccharide contributes to protective
immunity
To better understand the potential role of GP in conferring
protection against influenza viral infection, we tested the direct
effects of GP on viral infection in naı ¨ve mice. Mixtures of a lethal
dose (3 LD50) of the 2009 H1N1 virus (A/California/04/2009)
and GP were used to intranasally infect naı ¨ve mice. Naı ¨ve mice
that were infected with a mixture of virus and PBS buffer showed
severe body weight loss and all died (Fig. 5). In contrast, 2.5 mg/
kg and 25 mg/kg GP provided 33% and 66% protection to naı ¨ve
mice that were infected with a lethal dose of the 2009 H1N1 virus
mixed with GP although the surviving mice showed a visible body
weight loss similar to the infection in the PBS control (Mock).
Therefore, these results suggest that GP may have a direct effect
on improving the survival against influenza infection.
Lungs were collected at day 4 post infection to determine lung
viral titers and cytokine levels (Fig. 6). The GP treated group
showed lower lung viral titers by 2.5 fold compared to that of the
control group without GP (Fig. 6A). Also, the levels of
inflammatory cytokine IL-6 was found to be lower in the GP
treated group compared to the untreated control after lethal
infection (Fig. 6B). In contrast, interferon (IFN)-c was moderately
higher in lungs of GP-treated mice compared to the infected naı ¨ve
control mice (Fig. 6C). These results imply that GP-mediated
protection might be partially due to inhibiting lung viral
replication and inflammatory cytokines, and stimulating antiviral
cytokine IFN-c production.
Ginseng polysaccharide improves cross protection by
influenza vaccines
Immunization with inactivated viral vaccine usually induces
good protective immunity against the homologous virus infection
but not against a heterosubtypic influenza A virus. Influenza
virus-like particles (VLPs) have been suggested to be a promising
candidate vaccine [18,25]. Here, we determined the effects of
GP pretreatment on induction of heterosubtypic protection in
mice vaccinated with influenza VLPs containing HA and M1
derived from H1N1 A/PR8 virus (Fig. 7). Mice were intranasally
immunized with influenza VLPs (8 mg total protein). From day 1
post vaccination, groups of naı ¨v ea n dv a c c i n a t e dm i c ew e r e
treated daily with GP (5 mg/kg daily) via the intranasal route for
Figure 3. Ginseng polysaccharide pretreatment improved the
survival after infection with H3N2 influenza virus. A) Changes in
body weight (%). B) Survival rates (%). C) Lung viral titers at day 4 post
infection (n=4 out of 10 infected mice). BALB/c mice (n=10 , 12 weeks
old) were once pretreated intranasally with ginseng polysaccharide
(25 mg/kg) 6 hours prior to infection with H3N2 subtype A/Philippines/
82 virus (3 LD50). * p,0.05 between mock and GP groups.
doi:10.1371/journal.pone.0033678.g003
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lethal dose (6 LD50) of H3N2 subtype A/Philippines virus. All
naı ¨ve mice became very sick, rapidly lost body weight below
75% and died or were euthanized. Also, all mice in the A/PR8
VLP vaccinated group died although the vaccinated mice
showed a delay in mortality (Fig. 7A, 7B). The group of
Figure 4. Intravenous pretreatment with ginseng polysaccharide provided protection against lethal infection with H3N2 influenza
virus. A) Changes in body weight (%). B) Survival rates (%). Groups of mice (n=5) intravenously administered ginseng polysaccharide (10 or 25 mg/
kg) were infected with A/Philippines/82 virus (3 LD50), and survival rates monitored daily for 14 days. Mock: mice treated with PBS, GP 10 mg: mice
treated with 10 mg/kg ginseng polysaccharide, GP 25 mg: mice treated with 25 mg/kg ginseng polysaccharide.
doi:10.1371/journal.pone.0033678.g004
Figure 5. Ginseng polysaccharide effects on influenza infection. Mixtures of virus (A/California/2009, 3 LD50) and different amounts of
ginseng polysaccharide (2.5 mg/kg, 25 mg/kg) were used to infect mice intranasally (n=6). The body weight changes (A) and survival rates (B) were
monitored daily for 14 days. Mock: naı ¨ve mice infected with virus in PBS, GP 2.5 mg: naı ¨ve mice infected with a mixture of virus and 2.5 mg/kg of
ginseng polysaccharide, GP 25 mg: naı ¨ve mice infected with a mixture of virus and 25 mg/kg of ginseng polysaccharide.
doi:10.1371/journal.pone.0033678.g005
Figure 6. Lung viral titers and cytokines in mice infected with a mixture of ginseng polysaccharide and virus (A/California/2009, 3
LD50). Lung viral titers (A), interleukin (IL)-6 (B), and interferon (IFN)-c levels (C) were determined at day 4 post infection with a mixture of ginseng
polysaccharide and virus (A/California/2009, 3 LD50) (n=5). Mock: naı ¨ve mice infected with virus in PBS, GP 25 mg: naı ¨ve mice infected with a mixture
of virus and 25 mg/kg of ginseng polysaccharide. * p,0.05 between mock and GP 25 mg/kg groups as determined by Student’s t-test.
doi:10.1371/journal.pone.0033678.g006
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severe loss in body weight similar to that of vaccinated mice
without GP and showed 25% survival (data not shown).
Importantly, 80% of mice that were vaccinated with A/PR8
VLPs and treated with GP daily for 12 days were survived lethal
challenge with A/Philippines virus. Daily GP treatment did not
increase the immune responses to the viral antigen (Fig. 7C).
Also, daily treatment of a higher dose (25 mg/kg body) did not
improve the cross protective efficacy (data not shown). These
results suggest that daily GP treatment has the potential to
improve the cross protective vaccine efficacy.
Ginseng polysaccharide has antiviral activity
It would be of interest to determine whether GP treatment has
effects on viral growth. When influenza A/PR8 virus was mixed
with GP at different concentrations, the amounts of viral growth as
measured by a hemagglutination activity assay were moderately
lower up to 50% in a dose-dependent manner (Fig. 8A). High
amounts of GP concentrations (500, 1000 mg/ml) were required to
exhibit an inhibition effect on a high dose A/PR8 virus of
approximately 20,000 plaque forming units (PFU) per milliliter.
To determine the effects of GP on the growth of a different strain,
the 2009 H1N1 pandemic virus (A/California/2009) was tested
(Fig. 8B). The concentration of A/California/2009 virus was
approximately 4000 PFU per milliliter and GP amounts in a range
of up to 200 mg/ml were tested. Approximately five-fold lower
levels of A/California/2009 virus production were observed at the
GP concentration of 200 mg per milliliter (Fig. 8B). Also, a similar
pattern of virus growth inhibition was obtained when mixtures of
A/California/2009 virus and GP were used to infect eggs (data not
shown). Therefore, these results suggest that GP may have the
anti-viral growth activity against influenza viruses in a dose-
dependent but strain-independent pattern.
Discussion
Although GP has been known to have various immunomodu-
latory functions, its in vivo effects on viral infectious diseases are not
very well studied. For the first time, we have investigated the
effects of GP treatment on influenza virus infection in a mouse
model. Intranasal or intravenous administration of mice with GP
prior to infection conferred resistance to intranasal lethal infection
by different influenza strains, resulting in increased survival rates
but not preventing body weight loss. Also, naı ¨ve mice were
partially protected when a lethal dose of influenza virus was mixed
with GP prior to infection. Finally, intranasal pretreatment of
vaccinated mice with GP improved their survival against
heterosubtypic infection. Therefore, GP might have a preventive
effect on influenza infection.
Intranasal administration with GP was tested in this study since
influenza virus infects the host via the respiratory tract. The
survival benefit against both H1N1 (A/PR8) and H3N2 (A/
Philippines) viruses was observed with intranasal 25 mg/kg or
intravenous 10 mg/kg doses. Higher doses of GP pretreatments
did not increase the survival benefit. Although these dosage ranges
used in our study were similar to those reported by a previous
study demonstrating the beneficial effect of intravenous pretreat-
ment with GP on decreasing septic complications by intraperito-
neal infection with bacteria, variable optimum doses were
previously reported depending on different septic models
[16,17]. Also, we found that timing of pretreatments influenced
the efficacy of survival. Pretreatment more than one day earlier
decreased the survival benefit and treatment post influenza
infection did not improve protective efficacy (data not shown).
This is consistent with previous findings that GP or ginseng
treatment close to septic infection or after lipopolysaccharide
stimulation was less or not effective [17,26]. Further studies are
needed to better understand the mechanisms by which pretreat-
ments with GP exhibit survival benefit during influenza infection.
Pretreatment with GP resulted in lower lung viral titers than
those observed in the untreated mice at day 4 post infection. This
better control of lung viral replication observed was not because of
increased anti-viral antibody immune responses in the GP treated
group (data not shown). In support of this observation, beneficial
effects of GP pre-treatment were also observed in B cell-deficient
mice (data not shown). A possible mechanism is that GP may have
Figure 7. Ginseng polysaccharide enhances heterosubtypic
cross protection in vaccinated mice. (A) Body weight changes. (B)
Survival rates. Mice (n=5) that were intranasally vaccinated with
influenza VLPs (H1 VLP, 8 mg total protein) were intranasally treated
with ginseng polysaccharide (5 mg/kg) daily for 12 days prior to
infection with H3N2 heterosubtypic virus (A/Philippines/82, 6 LD50). (C)
A/PR/8/34 virus specific serum antibody levels. Virus- specific antibody
levels were determined in sera collected prior to challenge infection. H1
VLP: Vaccination with H1 VLPs, H1 VLP+GP: Daily treatment with GP for
12 days from the day 1 post vaccination with H1 VLPs, Mock:
unvaccinated mice infected with virus.
doi:10.1371/journal.pone.0033678.g007
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mixture of a 2009 H1N1 influenza virus and GP showed improved
survival compared to the control mice infected with the same dose
of virus in PBS. Moderate decreases were observed in lung viral
titers (approximately 2.5 fold) in the GP treated virus group. In this
regard, it is interesting to note that the replication of influenza
viruses mixed with GP was inhibited at moderate levels. However,
the requirement of high concentration of GP indicates that the
direct virucidal effects of GP are relatively weak and other
additional mechanisms might be involved in vivo.
GP was also demonstrated to enhance the production of
cytokines and reactive oxygen species by stimulating macrophages
[12,27]. In a recent study, GP was shown to stimulate dendritic
cells resulting in enhanced production of IFN-c [28]. In contrast,
intravenous pretreatment of GP attenuated the production of
serum pro- and anti-inflammatory cytokines after septic bacterial
infection [16]. Infection of mice with a mixture of virus and GP
resulted in higher levels of the antiviral cytokine IFN-c and lower
levels of proinflammatory cytokine IL-6 compared to those in the
mice infected with virus only. Taken together, this study and
others suggest a mechanism that GP might have antiviral activity
against influenza virus by modulating host cytokines.
Infection with pathogenic influenza virus was shown to induce
significant cell death probably via apoptosis causing tissue
damages as a pathogenic mechanism of influenza [29–32].
Constitutive ERK1/2 activation is known to be important for
the viability of malignant tumor/cancer cells and the phosphor-
ylation of ERK1/2 plays a critical role in activating genes involved
in cell cycle regulation and survival [33–35]. In preliminary
studies, we found that influenza infection of human lung epithelial
cell line (A549) induced significantly lower levels of ERK1/2
phosphorylation, indicating apoptosis-mediated cell death due to
influenza virus infection. Examination of influenza infected cells
under the microscope showed substantial cytopathic effects (data
not shown). Importantly, pretreatment with GP resulted in
preventing the down-regulation of ERK1/2 phosphorylation due
to the subsequent infection with influenza virus. GP treatment of
human lung epithelial cell line did not change the constitutive
phosphorylation of ERK1/2 after infection with influenza virus
(data not shown). Consistent with our observation, GP was
reported to significantly increase the viability of peritoneal
macrophage cells [36]. In addition, ginseng was shown to inhibit
degradation of long-lived proteins and to stimulate protein
synthesis similar to polypeptide growth factors [37]. Thus, it is
speculated that maintaining the cell viability under the condition
of viral infection-induced stress might be an another alternative
mechanism for the protective effects by GP.
It is highly significant to enhance the cross protective efficacy of
vaccination considering that current influenza vaccines induce
strain-specific protection. This study first demonstrated that
heterosubtypic protection of vaccinated mice was observed in
mice received GP treatment daily although treatment of
vaccinated mice with GP did not affect the host humoral immune
responses to the vaccine antigen. Most people who consume
ginseng are not immunologically naı ¨ve and are either vaccinated
or immune to certain infectious agents because of natural
exposure. It is also considered that immunomodulatory effects
by GP treatments might play an important role in the outcomes of
survival after influenza viral infection. Therefore, normal con-
sumption of ginseng containing GP in healthy individuals would
have beneficial effects on preventing unexpected influenza
infections.
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